Intellia to Present Phase 3 CRISPR Data for HAE Treatment at EAACI 2026 — Intellia Therapeutics, Inc.

Event summary

Intellia Therapeutics will present Phase 3 HAELO trial data for lonvo-z at EAACI 2026 in a late-breaking oral session on June 13, 2026.
Lonvo-z is a CRISPR-based gene editing therapy for hereditary angioedema (HAE) aiming for a one-time treatment solution.
The therapy has received multiple regulatory designations including Orphan Drug, RMAT, Innovation Passport, and PRIME.
A poster presentation will detail treatment barriers for HAE patients outside the U.S.

The big picture

Intellia's presentation of Phase 3 data for lonvo-z marks a critical milestone in the CRISPR gene editing field, potentially offering a one-time cure for HAE. The therapy's multiple regulatory designations highlight its strategic importance in addressing a rare disease with significant unmet needs. Success here could position Intellia as a leader in CRISPR-based therapies, influencing the broader gene editing market.

What we're watching

Regulatory Pathway: Whether the multiple regulatory designations will accelerate lonvo-z's approval process in key markets.
Clinical Efficacy: The extent to which Phase 3 data demonstrates lonvo-z's superiority over existing HAE treatments.
Market Adoption: The pace at which lonvo-z could gain acceptance among physicians and patients if approved.